{"nctId":"NCT00250458","briefTitle":"Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea","startDateStruct":{"date":"2006-03"},"conditions":["Migraine"],"count":346,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Comparator: Rizatriptan"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"Comparator: Rizatriptan","otherNames":[]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 6-month history of migraine, moderate to severe migraine attacks with nausea, 1-6 migraine attacks per month\n\nExclusion Criteria:\n\n* Heart disease, high blood pressure","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants With Elimination of Nausea at 2 Hours Postdose","description":"Participants reporting the absence of nausea at 2 hours post treatment. Absence or presence of nausea was recorded by the participants in an electronic diary. Absence is defined as no nausea at 2 hours post-treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"130","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Pain Relief at 2 Hours Postdose","description":"Participants reporting pain relief defined as a reduction of pain severity from grades 2 or 3 (moderate or severe pain) at baseline to grades 0 or 1 (no headache or mild pain) at 2 hours after treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":200},"commonTop":["Dizziness","Somnolence","Vision blurred","Diarrhoea","Dry mouth"]}}}